Allergan Notes Receipt of Paragraph IV Notification on Restasis

lergan plc

today confirmed that the Company has received a notice letter dated July 10, 2015 (the "Notice Letter") from Akorn Pharmaceuticals stating that the U.S. Food and Drug Administration (FDA) has received Akorn's Abbreviated New Drug Application (ANDA) containing a "Paragraph IV" patent certification seeking approval to market a generic version of Allergan's Restasis® (cyclosporine ophthalmic emulsion) 0.05% product. In addition, Allergan has received communication suggesting that additional ANDAs for generic versions of Restasis® may have been received by the FDA. Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO The Notice Letter received from Akorn states that the "Paragraph IV" patent certification was made with respect to certain U.S. patents covering the formulation and method of use of the Restasis® product, which are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Allergan has five Orange Book-listed patents covering Restasis® that are scheduled to expire in August 2024. Allergan is highly confident in its intellectual property rights relating to Restasis® and intends to vigorously enforce such rights in all applicable venues.